Viridian Therapeutics is a biotechnology business based in the US. Viridian Therapeutics shares (VRDN) are listed on the NASDAQ and all prices are listed in US Dollars. Viridian Therapeutics employs 50 staff and has a trailing 12-month revenue of around $1.9 million.
How to buy Viridian Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – VRDN. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Viridian Therapeutics stock price (NASDAQ: VRDN)
Use our graph to track the performance of VRDN stocks over time.Viridian Therapeutics shares at a glance
Latest market close | $37.30 |
---|---|
52-week range | $9.47 - $39.00 |
50-day moving average | $29.08 |
200-day moving average | $19.62 |
Wall St. target price | $47.08 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-5.14 |
Buy Viridian Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Viridian Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Viridian Therapeutics price performance over time
Historical closes compared with the close of $37.3 from 2023-02-01
1 week (2023-01-26) | -0.80% |
---|---|
1 month (2022-12-30) | 27.70% |
3 months (2022-11-02) | 93.46% |
6 months (2022-08-02) | 164.54% |
1 year (2022-02-02) | 101.51% |
---|---|
2 years (2021-02-02) | 81.95% |
3 years (2020-01-31) | 2,031.43% |
5 years (2018-02-02) | 333.72% |
Viridian Therapeutics financials
Revenue TTM | $1.9 million |
---|---|
Gross profit TTM | $-53,923,000 |
Return on assets TTM | -21.59% |
Return on equity TTM | -36.84% |
Profit margin | 0% |
Book value | $6.63 |
Market capitalisation | $1.5 billion |
TTM: trailing 12 months
Viridian Therapeutics share dividends
We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.
Have Viridian Therapeutics's shares ever split?
Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.
Viridian Therapeutics share price volatility
Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $9.47 up to $39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 0.9595. This would suggest that Viridian Therapeutics's shares are less volatile than average (for this exchange).
Viridian Therapeutics overview
Viridian Therapeutics, Inc. , a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc.
Viridian Therapeutics in the news
Zenas BioPharma 的合作夥伴 Viridian Therapeutics 宣佈正在進行的評估低劑量 VRDN-001 (ZB001) 治療甲狀腺眼病 (TED) 患者的 1/2 期試驗獲得積極數據
ゼナス・バイオファーマ (Zenas BioPharma) のパートナーであるヴィリジアン・セラピューティクス (Viridian Therapeutics)、甲状腺眼症 (TED) 患者を対象とした低用量VRDN-001 (ZB001) を評価する進行中の第1/2相試験で良好なデータが得られたことを発表
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Frequently asked questions
What percentage of Viridian Therapeutics is owned by insiders or institutions?Currently 1.41% of Viridian Therapeutics shares are held by insiders and 95.743% by institutions. How many people work for Viridian Therapeutics?
Latest data suggests 50 work at Viridian Therapeutics. When does the fiscal year end for Viridian Therapeutics?
Viridian Therapeutics's fiscal year ends in December. Where is Viridian Therapeutics based?
Viridian Therapeutics's address is: 221 Crescent Street, Waltham, MA, United States, 02453 What is Viridian Therapeutics's ISIN number?
Viridian Therapeutics's international securities identification number is: US92790C1045
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert